Online citations, reference lists, and bibliographies.
← Back to Search

Brief Report: A Phase II Study Of Sunitinib In Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group

S. Laurie, Ashish Gupta, Q. Chu, C. Lee, W. Morzycki, R. Feld, A. Foo, J. Seely, J. Goffin, F. Laberge, N. Murray, Sanjay Rao, G. Nicholas, Janessa L. Laskin, T. Reiman, D. Sauciuc, L. Seymour
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Introduction: Malignant pleural mesothelioma (MPM) is an aggressive malignancy that most often presents at an advanced, incurable stage. After the failure of standard first-line cisplatin/antifolate chemotherapy, there is no accepted treatment. The vascular endothelial growth factor pathway may be a relevant therapeutic target in MPM. Methods: This open-labeled phase II trial evaluated single-agent sunitinib, an inhibitor of multiple receptor tyrosine kinases including the vascular endothelial growth factor receptors, given at 50 mg daily orally for 4 weeks followed by a 2-week rest, in patients with advanced MPM. Two cohorts were studied: cohort 1, in which patients had previously received cisplatin-based chemotherapy, and cohort 2, consisting of previously untreated patients. A two-stage design was used for both cohorts; the primary outcome was objective response rate as determined by the RECIST criteria modified for MPM. Secondary outcomes included rates and duration of disease control, progression-free survival and overall survival, and safety and tolerability. Results: A total of 35 eligible patients were enrolled (17 to cohort 1 and 18 to cohort 2). Neither cohort met the criteria for continuing to the second stage of accrual; only one objective response, confirmed by independent review, was observed in a previously untreated patient. Median progression-free and overall survivals were 2.8 and 8.3 months in cohort 1, and 2.7 and 6.7 months in cohort 2, respectively. Observed toxicity was within that expected for sunitinib. Conclusions: Sunitinib, similar to other angiogenesis inhibitors, has limited activity in MPM. Future trials of angiogenesis inhibitors given as single agents in unselected patients with MPM are not warranted.
This paper references
A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria
A. Tsao (2011)
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM).
A. Nowak (2010)
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
P. Wheatley-Price (2010)
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
Optimal two-stage designs for phase II clinical trials.
R. Simon (1989)
Cancer Centre for the Southern Interior
T Do
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)

This paper is referenced by
A review of bevacizumab in the treatment of malignant pleural mesothelioma.
S. Brosseau (2017)
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
Gene expression of DNA repair proteins in colorectal cancer and medulloblastoma
K. Odufuwa (2019)
Malignant mesothelioma: new insights into a rare disease.
J. Remon (2013)
Advances in treatment of mesothelioma
C. Maggioni (2016)
Molecular pathogenesis of malignant mesothelioma.
P. Rascoe (2012)
Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements
D. Christoph (2014)
Searching for targets for the systemic therapy of mesothelioma.
R. Stahel (2015)
Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review
O. Abdel-Rahman (2015)
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
F. Petrelli (2018)
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
S. Papa (2013)
Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma.
M. Disselhorst (2020)
Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?
D. Signorelli (2016)
Actualités dans le mésothéliome malin pleural
L. Reviron-Rabec (2012)
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma
Y. Sekido (2018)
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies
A. Bononi (2015)
Second line therapy in malignant pleural mesothelioma: A systematic review.
W. Buikhuisen (2015)
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
Sungkyoung Kim (2014)
alignant pleural mesothelioma
F. Honeyball (2013)
Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice
G. Ceresoli (2014)
Emerging therapies in malignant pleural mesothelioma.
M. Cinausero (2019)
Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
T. Funakoshi (2013)
Molecular pathogenesis of malignant mesothelioma.
Y. Sekido (2013)
Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
B. Doonan (2017)
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really “Raising the Bar?”
V. Noia (2019)
Malignant pleural mesothelioma: an update on diagnosis and treatment options
Sanjana Kondola (2016)
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
Impact of relatively new chemotherapeutic agents on the outcome of Egyptian patients with advanced malignant pleural mesothelioma
Rabab Gaafar (2014)
A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes
W. Buikhuisen (2016)
Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
A. Tsao (2018)
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).
K. Parikh (2019)
Connexin 43 enhances Bax activation via JNK activation in sunitinib-induced apoptosis in mesothelioma cells.
Miaki Uzu (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar